ofloxacin has been researched along with Acinetobacter Infections in 8 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Acinetobacter Infections: Infections with bacteria of the genus ACINETOBACTER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levofloxacin (200 mg/kg) was 73% effective, and ciprofloxacin (35 mg/kg) was ineffective in preventing death." | 1.39 | Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients. ( Davies, TA; He, W; Lynch, AS; Queenan, AM, 2013) |
| " A hollow-fiber infection model (HFIM) simulating various clinical (fluctuating concentrations over time) dosing exposures was used to selectively validate our quantitative assessment of the combined killing effect." | 1.35 | Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii. ( Chang, KT; Hou, JG; Kwa, AL; Ledesma, KR; Lim, TP; Nikolaou, M; Prince, RA; Quinn, JP; Tam, VH, 2008) |
| "We evaluated the in vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia using a susceptible strain and one with low-level resistance (MIC/MBC of levofloxacin: 0." | 1.31 | In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia. ( Bryskier, A; Carbon, C; Farinotti, R; Joly-Guillou, ML; Wolff, M, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Queenan, AM | 1 |
| Davies, TA | 1 |
| He, W | 1 |
| Lynch, AS | 1 |
| Regalado, NG | 1 |
| Martin, G | 1 |
| Antony, SJ | 1 |
| Bhagan-Bruno, S | 1 |
| Lather, N | 1 |
| Fergus, IV | 1 |
| Ozbek, B | 1 |
| Sentürk, A | 1 |
| Lim, TP | 1 |
| Ledesma, KR | 1 |
| Chang, KT | 1 |
| Hou, JG | 1 |
| Kwa, AL | 1 |
| Nikolaou, M | 1 |
| Quinn, JP | 1 |
| Prince, RA | 1 |
| Tam, VH | 1 |
| Heinemann, B | 1 |
| Wisplinghoff, H | 1 |
| Edmond, M | 1 |
| Seifert, H | 1 |
| Joly-Guillou, ML | 1 |
| Wolff, M | 1 |
| Farinotti, R | 1 |
| Bryskier, A | 1 |
| Carbon, C | 1 |
| Valero, E | 1 |
| Sevillano, D | 1 |
| Calvo, A | 1 |
| García, R | 1 |
| Leturia, A | 1 |
| Gómez-Lus, ML | 1 |
8 other studies available for ofloxacin and Acinetobacter Infections
| Article | Year |
|---|---|
Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Carbapenems; Ciprofloxacin; Doripenem; D | 2013 |
Acinetobacter lwoffii: bacteremia associated with acute gastroenteritis.
Topics: Acinetobacter; Acinetobacter Infections; Acute Disease; Anti-Bacterial Agents; Bacteremia; Community | 2009 |
Acinetobacter endocarditis presenting as a large right atrial mass: an atypical presentation.
Topics: Acinetobacter Infections; Adult; Anti-Bacterial Agents; Catheters, Indwelling; Cefepime; Cephalospor | 2010 |
Postantibiotic effects of tigecycline, colistin sulfate, and levofloxacin alone or tigecycline-colistin sulfate and tigecycline-levofloxacin combinations against Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Colistin; Drug Resistance, | 2010 |
Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Infective Agents; Cefepime; Cephal | 2008 |
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Diseas | 2000 |
In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia.
Topics: Acinetobacter Infections; Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Area Unde | 2000 |
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].
Topics: Acinetobacter; Acinetobacter Infections; Ampicillin; Anti-Infective Agents; Aza Compounds; Cefepime; | 2001 |